Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Louisiana Insulin Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedBlue Cross and Blue Shield of LouisianaPolicy 00395

    Insulins (Non-Long Acting Products)

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy 00395 alerts

    Get alerted when Policy 00395 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage eligibility for non-long-acting insulin products outside the Novolin, Kirsty (insulin aspart-xjhz), and Insulin Lispro Authorized Branded Generic families, subject to the member contract.

    Policy Summary
    PayerBlue Cross and Blue Shield of Louisiana
    PolicyInsulins (Non-Long Acting Products)
    Policy CodePolicy 00395
    Change TypeModified
    Effective DateJan 1, 202743d
    Last ReviewJul 21, 2026
    Next Review DateJul 1, 2027
    Key ActionDocument clinical evidence or patient history showing that the preferred insulin families would be ineffective or cause an adverse reaction.
    SourceLink
    POLICY UPDATE CHANGES

    Afrezza was added to the insulin policy.

    Fiasp was added to the first-line products.

    Admelog was added to the policy.

    The insulin lispro branded generic was added to the policy.

    Fiasp was added to the first-line insulin products.

    Admelog was added to the policy.

    The Insulin Lispro branded generic was added to the policy.

    Merilog was added to the policy as a non-preferred product.

    A criterion was added requiring that concentrated insulin products not be used in an external insulin pump.

    Kirsty was added to the policy as a non-preferred product.

    Preferred insulin products were updated to Kirsty and insulin lispro products, while Novolog and Fiasp products were moved to non-preferred status.

    A criterion was added requiring that Humulin R U-500 not be used in an external insulin pump.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Preferred insulin families
    1Core patient-selection requirement
    2External-pump restrictions
    U-200/U-500Concentrated insulin products
    Type 1 and Type 2Applicable diabetes types

    Coverage Criteria

    Non-long-acting insulin coverage

    Coverage may be considered when all applicable requirements are met.

    • Preferred-family exception: Clinical evidence or patient history suggests that use of the Novolin, Kirsty, or Insulin Lispro Authorized Branded Generic family would be ineffective or cause an adverse reaction to the patient.

      This is an additional Company requirement and will be denied as not medically necessary if not met.

    • Concentrated-insulin pump safeguards when applicable

      • Lyumjev or Humalog U-200: For Lyumjev KwikPen U-200 and Humalog KwikPen U-200 requests, the prescriber provides the required attestation that the concentrated insulin will not be used in an external insulin pump when pump administration is not included in FDA-approved labeling or when use is inconsistent with the pump's FDA-cleared instructions for use.
      • Humulin R U-500: For Humulin R U-500 requests, the prescriber provides the required attestation that the concentrated insulin will not be used in an external insulin pump when pump administration is not included in FDA-approved labeling or when use is inconsistent with the pump's FDA-cleared instructions for use.

    Novolog Mix 70/30 is not subject to this policy.

    Long-acting insulin products, including Lantus, Toujeo, and Tresiba, are outside the scope of this policy.

    Investigational or experimental services are excluded from coverage. This includes drugs, devices, procedures, or other services provided under the investigational arm of a clinical trial or clinical study.

    Concentrated insulin products must not be used in an external insulin pump when pump administration is not included in the product's FDA-approved labeling or use is inconsistent with the pump's FDA-cleared instructions for use.

    Humulin R U-500 must not be used in an external insulin pump when pump administration is not included in the product's FDA-approved labeling or use is inconsistent with the pump's FDA-cleared instructions for use.

    Use of a non-long-acting insulin product outside the Novolin, Kirsty (insulin aspart-xjhz), or Insulin Lispro Authorized Branded Generic families is considered not medically necessary when the patient-selection criterion is not met or the use is not included in the stated criteria.

    Coverage requires clinical evidence or patient history indicating that the Novolin, Kirsty, or Insulin Lispro Authorized Branded Generic family would be ineffective or cause an adverse reaction. Failure to establish this requirement is denied as not medically necessary.

    Provider Actions and Determination Risks

    Documentation Required

    Coverage Eligibility Review

    Review coverage eligibility for a non-long-acting insulin product outside the Novolin, Kirsty (insulin aspart-xjhz), or Insulin Lispro [Authorized branded Generic] preferred families only after the applicable patient-selection criteria are addressed and benefits are available under the member’s contract.

    • Novolog Mix 70/30 is not subject to this policy.
    • Concentrated insulins have a strength greater than 100 units/mL.
    Prior Authorization

    Concentrated Insulin Attestation

    For Lyumjev Kwikpen U-200 and Humalog Kwikpen U-200 requests, the prescriber must attest that the concentrated insulin will not be used in an external insulin pump when pump administration is not included in the product’s FDA-approved labeling or is inconsistent with the pump’s FDA-cleared instructions for use.

    • External insulin pumps include tubed and tubeless systems.

    Clinical Background

    Insulin is indicated for patients with Type 1 or Type 2 diabetes mellitus. Available formulations include regular, NPH, rapid-acting, mixed, and long-acting insulin. This policy addresses non-long-acting products and distinguishes standard U-100 insulin from concentrated formulations such as U-200, U-300, and U-500.

    Policy Definitions

    External insulin pump
    DefinitionAn insulin delivery device designed to provide continuous subcutaneous insulin infusion.
    System typesExternal insulin pumps include tubed and tubeless systems.
    ExamplesExamples include Omnipod DASH, Omnipod 5, twiist, Tandem t:slim X2, Tandem Mobi, Medtronic MiniMed 780G/770G/630G, and iLet Bionic Pancreas.
    Concentrated insulin
    DefinitionInsulin formulated at a strength greater than 100 units per mL.
    ExamplesConcentrated formulations include U-200, U-300, and U-500 insulin.
    Administration requirement

    Initial Therapy

    Initial therapy

    Initial coverage of a non-long-acting insulin product outside the preferred families requires the following criteria.

    Initial non-long-acting insulin therapy: Clinical evidence or patient history suggests that the Novolin, Kirsty, or Insulin Lispro Authorized Branded Generic family would be ineffective or cause an adverse reaction; and, when applicable, the prescriber provides the required concentrated-insulin external-pump attestation.

    Novolog Mix 70/30 is not subject to this policy.

    Step Therapy Requirements

    StepRequirementFailure criteria
    1Use or consider the Novolin, Kirsty (insulin aspart-xjhz), or Insulin Lispro Authorized Branded Generic family before coverage of other non-long-acting insulin products is considered.Clinical evidence or patient history must show that the preferred family would be ineffective or cause an adverse reaction; no trial duration is specified.
    StepProductPolicy placement
    1FiaspIdentified as a first-line product in the policy history.

    Biosimilar and Interchangeability Notes

    Billing Rule

    Kirsty is interchangeable with Novolog

    Kirsty is described as biosimilar to and interchangeable with Novolog. For applicable labeled conditions of use, the policy states there is no advantage to using Novolog over Kirsty.

    • Kirsty: insulin aspart-xjhz.
    • Consider the policy’s preferred-product positioning when selecting or requesting Novolog.
    Billing Rule

    Merilog is non-preferred and not interchangeable

    Merilog is described as biosimilar to Novolog but is not interchangeable with Novolog. The policy lists Merilog among non-preferred products subject to the coverage criteria.

    • Merilog: insulin-aspart-szjj.
    • Apply the coverage criteria for a non-preferred product when requesting Merilog.
    Policy Summary
    PayerBlue Cross and Blue Shield of Louisiana
    PolicyInsulins (Non-Long Acting Products)
    Policy CodePolicy 00395
    Change TypeModified
    Effective DateJan 1, 202743d
    Last ReviewJul 21, 2026
    Next Review DateJul 1, 2027
    Key ActionDocument clinical evidence or patient history showing that the preferred insulin families would be ineffective or cause an adverse reaction.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Determination RisksClinical BackgroundPolicy DefinitionsInitial TherapyStep Therapy RequirementsBiosimilar and Interchangeability Notes
  1. The attestation addresses use in an external pump, including systems such as Omnipod, Tandem, Medtronic MiniMed, and iLet.
  2. Step Therapy

    Preferred Insulin Family Requirement

    Before requesting another non-long-acting insulin product, establish use of or consideration of the Novolin, Kirsty (insulin aspart-xjhz), or Insulin Lispro [Authorized branded Generic] family. The Company considers products outside these preferred families eligible only when the policy’s patient-selection criteria are met.

    • Preferred-family products include the Novolin, Kirsty, and Insulin Lispro [Authorized branded Generic] families.
    • This policy does not apply to long-acting insulin products such as Lantus, Toujeo, or Tresiba.
    Documentation Required

    Document Failure or Intolerance

    Document clinical evidence or patient history showing that use of the preferred insulin families will be ineffective or cause an adverse reaction to the patient.

    • The evidence or history must support ineffectiveness or an adverse reaction.
    • This is an additional Company requirement for coverage eligibility.

    Unsupported block type: prior_auth

    Documentation Required

    Prior Authorization Transition Documentation

    When a member changes health plans during an ongoing course of treatment, Louisiana Blue may honor the prior health plan’s authorization for the same service under the same type of in-network benefit for a 90-day transition period. The member or provider must submit documentation of the prior authorization, and the service must otherwise be covered under the Louisiana Blue plan.

    • Transition recognition is discretionary and subject to contract, benefit, and coverage requirements.
    • Provide the prior health plan’s authorization documentation.
    Denial Risk

    Preferred-Family Criterion Not Met

    A request may be denied as not medically necessary if the required clinical evidence or patient history does not show that the preferred insulin families will be ineffective or cause an adverse reaction.

    • The preferred-family criterion is an additional Company requirement for coverage eligibility.
    Denial Risk

    Unsupported Concentrated-Insulin Pump Use

    Concentrated insulin used in an external insulin pump without FDA-approved pump labeling or outside the pump’s FDA-cleared instructions for use may be denied as investigational.

    • This restriction applies when pump administration is not included in the concentrated insulin product’s FDA-approved labeling.
    • Investigational services, including drugs, devices, procedures, or biological products, are not covered.
    Denial Risk

    Use Outside Policy Criteria

    Use of a non-long-acting insulin product outside the stated patient-selection criteria is considered not medically necessary.

    • The criterion applies to products outside the Novolin, Kirsty, or Insulin Lispro [Authorized branded Generic] families when the required selection criteria are not met or the use is not included in those criteria.
    Denial Risk

    Investigational or Experimental Service

    Investigational medical treatments, procedures, drugs, devices, and biological products are not covered. Concentrated-insulin use in an external pump may be considered investigational when it lacks FDA-approved pump labeling or does not follow the pump’s FDA-cleared instructions for use.

    • Investigational services are excluded from coverage under benefits.
    • Coverage determinations remain subject to applicable contract language and law.
    Denial Risk

    Concentrated Insulin in External Pump

    Use of concentrated insulin in an external insulin pump may trigger denial when pump administration is not included in the concentrated insulin product’s FDA-approved labeling or is inconsistent with the pump’s FDA-cleared instructions for use.

    • The policy added a criterion requiring that concentrated insulin products not be used in an external insulin pump under the stated circumstances.
    Denial Risk

    Humulin R U-500 in External Pump

    Humulin R U-500 used in an external insulin pump may be denied when pump administration is not included in the product’s FDA-approved labeling or when use is not in accordance with the pump’s FDA-cleared instructions for use.

    • A specific Humulin R U-500 external-pump restriction was added to the policy.
    Concentrated insulin products must not be administered using an insulin pump under the FDA-approved labeling described in the policy.
    Biosimilar
    DefinitionA biological product approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as the reference product.
    Clinical differencesThere are no clinically meaningful differences between the biosimilar product and the reference product.
    Policy examplesMerilog and Kirsty are identified as biosimilars to Novolog; Kirsty is designated interchangeable with Novolog, while Merilog is not interchangeable with Novolog.
    U-100 insulin
    DefinitionU-100 insulin is the standard insulin concentration used in most clinical settings.
    Delivery compatibilityIt is compatible with the widest range of delivery devices.
    Compatible devicesCompatible devices include syringes, pen devices, and external insulin pumps.
    Medically Necessary
    DefinitionHealth care services, treatment, procedures, equipment, drugs, devices, items, or supplies that a provider exercising prudent clinical judgment would provide to prevent, evaluate, diagnose, or treat an illness, injury, disease, or its symptoms.
    Clinical standardsThe service, treatment, or item must be in accordance with nationally accepted standards of medical practice and clinically appropriate and effective for the patient's illness, injury, or disease.
    Cost and convenienceIt must not be primarily for personal comfort or convenience and must not be more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results.
    Investigational
    DefinitionA medical treatment, procedure, drug, device, or biological product is investigational if its effectiveness has not been clearly tested and it has not been incorporated into standard medical practice.
    FDA statusThe determination considers whether the treatment, procedure, drug, device, or biological product can be lawfully marketed without FDA approval and whether FDA approval has been granted when it is sought to be furnished.
    Further evidenceThe determination also considers whether further studies or clinical trials are needed to establish maximum tolerated dose, toxicity, safety, effectiveness, comparative effectiveness, or improved health outcomes.